Asset Details
Do you wish to reserve the book?
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Do you wish to request the book?
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
2015
Overview
In two placebo-controlled phase 3 trials, secukinumab, an anti–interleukin-17A monoclonal antibody, was effective in patients with ankylosing spondylitis. Adverse events associated with secukinumab included infections and neutropenia.
Ankylosing spondylitis is a chronic, immune-mediated disease that is characterized by inflammation and new bone formation in the axial skeleton
1
,
2
and that often results in progressive, irreversible structural damage, disability, deterioration of functioning, and a reduced quality of life.
3
,
4
Therapy with nonsteroidal antiinflammatory drugs (NSAIDs) is often insufficient to control symptoms, and there is no evidence that conventional disease-modifying antirheumatic drugs (DMARDs) are efficacious in axial disease.
5
Anti–tumor necrosis factor (TNF) therapy is currently recommended for patients with persistent disease activity despite conventional treatment.
5
In some patients, however, such therapy fails to achieve adequate disease control or has . . .
Publisher
Massachusetts Medical Society
Subject
/ Antibodies, Monoclonal - administration & dosage
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized
/ Crohn Disease - chemically induced
/ Female
/ Humans
/ Interleukin-17 - antagonists & inhibitors
/ Male
/ Neutropenia - chemically induced
/ Patients
